Trial · NCT04642950

A Phase II/III Study of Sargramostim

NCT04642950, Phase 2, Phase 3, Completed, Nobelpharma; results first posted 2024-07-19

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Phase II/III Study of Sargramostim. Trials, record NCT04642950. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04642950

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Phase II/III Study of Sargramostim
NCT number: NCT04642950
Status: Completed
Phases: Phase 2, Phase 3
Enrollment: 70 participants, actual
Lead sponsor: Nobelpharma
Conditions: COVID-19
Interventions: Sargramostim, Placebo
First posted: 2020-11-24
Last updated: 2024-07-19
Results first posted: 2024-07-19

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	2-rank Improvement on a 7-point Ordinal Scale	Period until Day 28 (including the case after discharge).	Number of days to achieve at least 2-rank improvement on a 7-point ordinal scale from baseline until Day 28.
Secondary	Changes From Baseline in Alveolar-arterial Oxygen Partial Pressure Gradient (A-aDO)	Period until Day 28 (including the case after discharge).	Changes from baseline in alveolar-arterial oxygen partial pressure gradient (A-aDO) on Day 5 and at the end of administration.
Secondary	Number of Days Until Discharge From Baseline	Period until Day 28 (including the case after discharge).	Number of days until discharge from baseline (days of shifting to Category 7 on a 7-point ordinal scale).
Secondary	Proportion of Subjects Whose Category Has Shifted to Category 1 or 2	Period until Day 28 (including the case after discharge).	Proportion of subjects whose category has shifted to Category 1 or 2 on a 7-point ordinal scale from baseline until Day 28

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	2-rank Improvement on a 7-point Ordinal Scale	Period until Day 28 (including the case after discharge).	Number of Days	MEDIAN
SECONDARY	Changes From Baseline in Alveolar-arterial Oxygen Partial Pressure Gradient (A-aDO)	Period until Day 28 (including the case after discharge).
SECONDARY	Number of Days Until Discharge From Baseline	Period until Day 28 (including the case after discharge).
SECONDARY	Proportion of Subjects Whose Category Has Shifted to Category 1 or 2	Period until Day 28 (including the case after discharge).

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
2-rank Improvement on a 7-point Ordinal Scale	NPC-26		9	95% Confidence Interval 8 to 9	Number of Days
2-rank Improvement on a 7-point Ordinal Scale	NP-26 Placebo		8	95% Confidence Interval 7 to 10	Number of Days

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	NPC-26	47
Overall Study	STARTED	NP-26 Placebo	23
Overall Study	COMPLETED	NPC-26	44
Overall Study	COMPLETED	NP-26 Placebo	23
Overall Study	NOT COMPLETED	NPC-26	3
Overall Study	NOT COMPLETED	NP-26 Placebo	0

Source ClinicalTrials.gov

Adverse events14

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Constipation	Gastrointestinal disorders	NPC-26	7	47
other	Constipation	Gastrointestinal disorders	NP-26 Placebo	4	23
other	Hepatocellular injury	Hepatobiliary disorders	NPC-26	3	47
other	Hepatocellular injury	Hepatobiliary disorders	NP-26 Placebo	0	23
other	White blood cell count increased	Investigations	NPC-26	7	47
other	White blood cell count increased	Investigations	NP-26 Placebo	0	23
other	Hyperglycemia	Metabolism and nutrition disorders	NPC-26	4	47
other	Hyperglycemia	Metabolism and nutrition disorders	NP-26 Placebo	1	23
other	Insomnia	Psychiatric disorders	NPC-26	1	47
other	Insomnia	Psychiatric disorders	NP-26 Placebo	3	23

1 to 10 of 14Source ClinicalTrials.gov

See all 14 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	NPC-26	0	47
Total, all-cause mortality	NP-26 Placebo	0	23
Total, other adverse events	NPC-26	22	47
Total, other adverse events	NP-26 Placebo	8	23
Total, serious adverse events	NPC-26	2	47
Total, serious adverse events	NP-26 Placebo	0	23

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
37729076	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
NPC-26 vs NP-26 Placebo: deaths from any cause	Trial comparisons
NPC-26 vs NP-26 Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04642950

GET https://conductscience.org/api/trials/v1/NCT04642950/registered

API reference For AI assistants